• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Microbiol. Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Test

tetano

Editor, Senior Moderator
J Clin Microbiol. 2020 May 4. pii: JCM.00926-20. doi: 10.1128/JCM.00926-20. [Epub ahead of print]
Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Test.


Loeffelholz MJ[SUP]1[/SUP], Alland D[SUP]2[/SUP], Butler-Wu SM[SUP]3[/SUP], Pandey U[SUP]4[/SUP], Perno CF[SUP]5[/SUP], Nava A[SUP]5[/SUP], Carroll KC[SUP]6[/SUP], Mostafa H[SUP]6[/SUP], Davies E[SUP]7[/SUP], McEwan A[SUP]7[/SUP], Rakeman JL[SUP]8[/SUP], Fowler RC[SUP]8[/SUP], Pawlotsky JM[SUP]9[/SUP], Fourati S[SUP]9[/SUP], Banik S[SUP]2[/SUP], Banada PP[SUP]2[/SUP], Swaminathan S[SUP]2[/SUP], Chakravorty S[SUP]10[/SUP], Kwiatkowski RW[SUP]10[/SUP], Chu VC[SUP]10[/SUP], Kop J[SUP]10[/SUP], Gaur R[SUP]10[/SUP], Sin MLY[SUP]10[/SUP], Nguyen D[SUP]10[/SUP], Singh S[SUP]10[/SUP], Zhang N[SUP]10[/SUP], Persing DH[SUP]10[/SUP].

Author information




Abstract

Background. Nucleic acid amplification tests (NAATs) are the primary means of identifying acute infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Accurate and fast test results may permit more efficient use of protective and isolation resources and allow for rapid therapeutic interventions.Methods. We evaluated the analytical and clinical performance characteristics of the Xpert? Xpress SARS-CoV-2 (Xpert) test, a rapid, automated molecular test for SARS-CoV-2. Analytical sensitivity and specificity/interference were assessed with infectious SARS-CoV-2, other infectious coronavirus species including SARS-CoV, and 85 nasopharyngeal swab specimens positive for other respiratory viruses including endemic human coronaviruses (hCoVs). Clinical performance was assessed using 483 remnant upper and lower respiratory specimens previously analyzed by standard of care (SOC) NAATs.Results. The limit of detection of the Xpert test was 0.01 plaque forming units (PFU)/mL. Other hCoVs, including Middle East Respiratory Syndrome coronavirus, were not detected by the Xpert test. SARS-CoV, a closely related species in the Sarbecovirus subgenus, was detected by a broad-range target (E) but was distinguished from SARS-CoV-2 (SARS-CoV-2-specific N2 target). Compared to SOC NAATs, the positive agreement of the Xpert test was 219/220 (99.5%) and the negative agreement was 250/261 (95.8%). A third tie-breaker NAAT resolved all but three of the discordant results in favor the Xpert test.Conclusions. The Xpert test provided sensitive and accurate detection of SARS-CoV-2 in a variety of upper and lower respiratory tract specimens. The high sensitivity and fast time to results of approximately 45 minutes may impact patient management.
Copyright ? 2020 American Society for Microbiology.



PMID:32366669DOI:10.1128/JCM.00926-20
 
Back
Top